Tags

Type your tag names separated by a space and hit enter

Uropontin in urinary calcium stone formation.
Miner Electrolyte Metab. 1994; 20(6):385-92.ME

Abstract

Normal urine is frequently supersaturated with respect to calcium oxalate. Thus, urinary inhibitors of crystallization appear to have an important role in preventing urinary stone formation. Uropontin was isolated by monoclonal antibody immunoaffinity chromatography and has the same N-terminal sequence as osteopontin derived from bone. This urinary form of osteopontin is a potent inhibitor of calcium oxalate monohydrate crystal growth at concentrations (approximately 0.1 microM) that normally prevail in human urine. Interaction with calcium oxalate monohydrate in vivo was shown by analysis of EDTA extracts of calcium stones. Uropontin is an abundant component of calcium oxalate monohydrate stones and present in only trace quantities in calcium oxalate dihydrate and hydroxyapatite stones. However, the precise role of uropontin in the pathogenesis of urinary stone formation is not known and is the subject of ongoing investigations.

Authors+Show Affiliations

Department of Pediatrics, University of Pennsylvania, Philadelphia, USA.

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

7783701

Citation

Hoyer, J R.. "Uropontin in Urinary Calcium Stone Formation." Mineral and Electrolyte Metabolism, vol. 20, no. 6, 1994, pp. 385-92.
Hoyer JR. Uropontin in urinary calcium stone formation. Miner Electrolyte Metab. 1994;20(6):385-92.
Hoyer, J. R. (1994). Uropontin in urinary calcium stone formation. Mineral and Electrolyte Metabolism, 20(6), 385-92.
Hoyer JR. Uropontin in Urinary Calcium Stone Formation. Miner Electrolyte Metab. 1994;20(6):385-92. PubMed PMID: 7783701.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Uropontin in urinary calcium stone formation. A1 - Hoyer,J R, PY - 1994/1/1/pubmed PY - 1994/1/1/medline PY - 1994/1/1/entrez SP - 385 EP - 92 JF - Mineral and electrolyte metabolism JO - Miner Electrolyte Metab VL - 20 IS - 6 N2 - Normal urine is frequently supersaturated with respect to calcium oxalate. Thus, urinary inhibitors of crystallization appear to have an important role in preventing urinary stone formation. Uropontin was isolated by monoclonal antibody immunoaffinity chromatography and has the same N-terminal sequence as osteopontin derived from bone. This urinary form of osteopontin is a potent inhibitor of calcium oxalate monohydrate crystal growth at concentrations (approximately 0.1 microM) that normally prevail in human urine. Interaction with calcium oxalate monohydrate in vivo was shown by analysis of EDTA extracts of calcium stones. Uropontin is an abundant component of calcium oxalate monohydrate stones and present in only trace quantities in calcium oxalate dihydrate and hydroxyapatite stones. However, the precise role of uropontin in the pathogenesis of urinary stone formation is not known and is the subject of ongoing investigations. SN - 0378-0392 UR - https://www.unboundmedicine.com/medline/citation/7783701/Uropontin_in_urinary_calcium_stone_formation_ L2 - https://antibodies.cancer.gov/detail/CPTC-SPP1-1 DB - PRIME DP - Unbound Medicine ER -